News
4d
Asianet Newsable on MSNSoleno Therapeutics Stock Slumps After Scorpion Capital Reveals Short Position: But Retail’s Not Pessimistic Yet
The shortseller alleged several risks associated with Vykat XR, including high risk of pre-diabetes/diabetes, pulmonary edema ...
Children were reportedly hospitalized after starting treatment. Scorpion Capital suggests Soleno's medication could face ...
Scorpion Capital disclosed a short position in Soleno Therapeutics on Friday, citing issues with the drugmaker's recently approved treatment Vykat XR, sending its shares slumping 15% in premarket ...
Soleno Therapeutics Inc (NASDAQ:SLNO) stock fell 13% Friday morning following a short report from Scorpion Capital that raised serious concerns about the company’s recently approved Prader-Willi ...
Stock futures were mixed on Friday as investors awaited a high-stakes meeting between U.S. and Russian leaders to discuss a ...
Soleno Therapeutics (SLNO) dropped 16% in premarket trading after a new short report from Scorpion Capital. Scorpion Capital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results